Advanced Search

Project: Therapies for Clinically Localized Prostate Cancer [Entered Retrospectively]

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Therapies for Clinically Localized Prostate Cancer Extraction Form Victoria Nelson 1

Associated Studies (each link opens a new tab)

Title Author Year
External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. Abugharib AE., Dess RT., Soni PD., Narayana V., Evans C., Gaber MS., Feng FY., McLaughlin PW., Spratt DE. -- Not Found --
Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Amini A., Jones BL., Jackson MW., Rusthoven CG., Maroni P., Kavanagh BD., Raben D. -- Not Found --
Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting). Ansmann L., Winter N., Ernstmann N., Heidenreich A., Weissbach L., Herden J. 2018
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Azzouzi AR., Vincendeau S., Barret E., Cicco A., Kleinclauss F., van der Poel HG., Stief CG., Rassweiler J., Salomon G., Solsona E., Alcaraz A., Tammela TT., Rosario DJ., Gomez-Veiga F., Ahlgren G., Benzaghou F., Gaillac B., Amzal B., Debruyne FM., Fromont G., Gratzke C., Emberton M. 2017
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. Barocas DA., Alvarez J., Resnick MJ., Koyama T., Hoffman KE., Tyson MD., Conwill R., McCollum D., Cooperberg MR., Goodman M., Greenfield S., Hamilton AS., Hashibe M., Kaplan SH., Paddock LE., Stroup AM., Wu XC., Penson DF. 2017
Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. Berlin A., Ahmad AE., Chua MLK., Moraes FY., Jiang H., Komisarenko M., Trimilshina N., Raziee H., Hosni A., Murgic J., Chung P., Bristow RG., Finelli A. 2018
Radical prostatectomy or watchful waiting in early prostate cancer. Bill-Axelson A., Holmberg L., Garmo H., Rider JR., Taari K., Busch C., Nordling S., Häggman M., Andersson SO., Spångberg A., Andrén O., Palmgren J., Steineck G., Adami HO., Johansson JE. 2014
Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. Bill-Axelson A., Holmberg L., Garmo H., Taari K., Busch C., Nordling S., Häggman M., Andersson SO., Andrén O., Steineck G., Adami HO., Johansson JE. 2018
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. Bolla M., Maingon P., Carrie C., Villa S., Kitsios P., Poortmans PM., Sundar S., van der Steen-Banasik EM., Armstrong J., Bosset JF., Herrera FG., Pieters B., Slot A., Bahl A., Ben-Yosef R., Boehmer D., Scrase C., Renard L., Shash E., Coens C., van den Bergh AC., Collette L. 2016
Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. Chang P., Regan MM., Ferrer M., Guedea F., Patil D., Wei JT., Hembroff LA., Michalski JM., Saigal CS., Litwin MS., Hamstra DA., Kaplan ID., Ciezki JP., Klein EA., Kibel AS., Sandler HM., Dunn RL., Crociani CM., Sanda MG. 2017
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. Donovan JL., Hamdy FC., Lane JA., Mason M., Metcalfe C., Walsh E., Blazeby JM., Peters TJ., Holding P., Bonnington S., Lennon T., Bradshaw L., Cooper D., Herbert P., Howson J., Jones A., Lyons N., Salter E., Thompson P., Tidball S., Blaikie J., Gray C., Bollina P., Catto J., Doble A., Doherty A., Gillatt D., Kockelbergh R., Kynaston H., Paul A., Powell P., Prescott S., Rosario DJ., Rowe E., Davis M., Turner EL., Martin RM., Neal DE. 2016
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Evans JR., Zhao S., Daignault S., Sanda MG., Michalski J., Sandler HM., Kuban DA., Ciezki J., Kaplan ID., Zietman AL., Hembroff L., Feng FY., Suy S., Skolarus TA., McLaughlin PW., Wei JT., Dunn RL., Finkelstein SE., Mantz CA., Collins SP., Hamstra DA. 2015
Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer. Falchook AD., Basak R., Mohiuddin JJ., Chen RC. 2016
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. Fosså SD., Wiklund F., Klepp O., Angelsen A., Solberg A., Damber JE., Hoyer M., Widmark A. 2016
Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. Gershman B., Psutka SP., McGovern FJ., Dahl DM., Tabatabaei S., Gettman MT., Frank I., Carlson RE., Rangel LJ., Barry MJ., Blute ML., Karnes RJ. 2016
Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer. Goy BW., Burchette R., Soper MS., Chang T., Cosmatos HA. 2020
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. Hamdy FC., Donovan JL., Lane JA., Mason M., Metcalfe C., Holding P., Davis M., Peters TJ., Turner EL., Martin RM., Oxley J., Robinson M., Staffurth J., Walsh E., Bollina P., Catto J., Doble A., Doherty A., Gillatt D., Kockelbergh R., Kynaston H., Paul A., Powell P., Prescott S., Rosario DJ., Rowe E., Neal DE. 2016
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Hamdy FC., Elliott D., le Conte S., Davies LC., Burns RM., Thomson C., Gray R., Wolstenholme J., Donovan JL., Fitzpatrick R., Verrill C., Gleeson F., Singh S., Rosario D., Catto JW., Brewster S., Dudderidge T., Hindley R., Emara A., Sooriakumaran P., Ahmed HU., Leslie TA. 2018
The Treatment of Localized Prostate Cancer in Everyday Practice in Germany. Herden J., Ansmann L., Ernstmann N., Schnell D., Weißbac L. 2016
Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. Herlemann A., Cowan JE., Carroll PR., Cooperberg MR. 2018
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Hoffman KE., Penson DF., Zhao Z., Huang LC., Conwill R., Laviana AA., Joyce DD., Luckenbaugh AN., Goodman M., Hamilton AS., Wu XC., Paddock LE., Stroup A., Cooperberg MR., Hashibe M., O'Neil BB., Kaplan SH., Greenfield S., Koyama T., Barocas DA. 2020
Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Hoffman RM., Lo M., Clark JA., Albertsen PC., Barry MJ., Goodman M., Penson DF., Stanford JL., Stroup AM., Hamilton AS. 2017
A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Knipper S., Pecoraro A., Palumbo C., Rosiello G., Luzzago S., Tian Z., Briganti A., Saad F., Tilki D., Graefen M., Karakiewicz PI. 2019
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. Lane A., Metcalfe C., Young GJ., Peters TJ., Blazeby J., Avery KN., Dedman D., Down L., Mason MD., Neal DE., Hamdy FC., Donovan JL. 2016
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lane JA., Donovan JL., Davis M., Walsh E., Dedman D., Down L., Turner EL., Mason MD., Metcalfe C., Peters TJ., Martin RM., Neal DE., Hamdy FC. 2014
Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. Lee DJ., Barocas DA., Zhao Z., Huang LC., Resnick MJ., Koyoma T., Conwill R., McCollum D., Cooperberg MR., Goodman M., Greenfield S., Hamilton AS., Hashibe M., Kaplan SH., Paddock LE., Stroup AM., Wu XC., Penson DF., Hoffman KE. 2018
Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. Loeb S., Meyer CP., Krasnova A., Curnyn C., Reznor G., Kibel AS., Lepor H., Trinh QD. 2016
Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. Malone S., Roy S., Eapen L., E C., MacRae R., Perry G., Bowen J., Samant R., Morgan S., Craig J., Malone K., Grimes S. 2020
Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. McDuff SGR., Chen MH., Renshaw AA., Loffredo MJ., Kantoff PW., D'Amico AV. 2018
PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. McPartlin AJ., Glicksman R., Pintilie M., Tsuji D., Mok G., Bayley A., Chung P., Bristow RG., Gospodarowicz MK., Catton CN., Milosevic M., Warde PR. 2016
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Morris WJ., Tyldesley S., Rodda S., Halperin R., Pai H., McKenzie M., Duncan G., Morton G., Hamm J., Murray N. 2017
Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Muralidhar V., Xiang M., Orio PF., Martin NE., Beard CJ., Feng FY., Hoffman KE., Nguyen PL. 2016
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. Neal DE., Metcalfe C., Donovan JL., Lane JA., Davis M., Young GJ., Dutton SJ., Walsh EI., Martin RM., Peters TJ., Turner EL., Mason M., Bryant R., Bollina P., Catto J., Doherty A., Gillatt D., Gnanapragasam V., Holding P., Hughes O., Kockelbergh R., Kynaston H., Oxley J., Paul A., Paez E., Rosario DJ., Rowe E., Staffurth J., Altman DG., Hamdy FC. 2020
Five-year Outcomes for a Prospective Randomised Controlled Trial Comparing Laparoscopic and Robot-assisted Radical Prostatectomy. Porpiglia F., Fiori C., Bertolo R., Manfredi M., Mele F., Checcucci E., De Luca S., Passera R., Scarpa RM. 2018
Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. Robinson D., Garmo H., Lissbrant IF., Widmark A., Pettersson A., Gunnlaugsson A., Adolfsson J., Bratt O., Nilsson P., Stattin P. 2018
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Rodda S., Morris WJ., Hamm J., Duncan G. 2017
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Rodda S., Tyldesley S., Morris WJ., Keyes M., Halperin R., Pai H., McKenzie M., Duncan G., Morton G., Hamm J., Murray N. 2017
Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. Sooriakumaran P., Pini G., Nyberg T., Derogar M., Carlsson S., Stranne J., Bjartell A., Hugosson J., Steineck G., Wiklund PN. 2018
Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. Thomsen FB., Røder MA., Jakobsen H., Langkilde NC., Borre M., Jakobsen EB., Frey A., Lund L., Lunden D., Dahl C., Brasso K. 2019
Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Tosoian JJ., Sundi D., Trock BJ., Landis P., Epstein JI., Schaeffer EM., Carter HB., Mamawala M. 2016
Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. Tward JD., Jarosek S., Chu H., Thorpe C., Shrieve DC., Elliott S. 2016
Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Tyson MD., Alvarez J., Koyama T., Hoffman KE., Resnick MJ., Wu XC., Cooperberg MR., Goodman M., Greenfield S., Hamilton AS., Hashibe M., Paddock LE., Stroup A., Chen VW., Penson DF., Barocas DA. 2017
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Tyson MD., Koyama T., Lee D., Hoffman KE., Resnick MJ., Wu XC., Cooperberg MR., Goodman M., Greenfield S., Hamilton AS., Hashibe M., Paddock LE., Stroup A., Chen V., Conwill R., McCollum D., Penson DF., Barocas DA. 2018
Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Viani GA., Viana BS., Martin JE., Rossi BT., Zuliani G., Stefano EJ. 2016
HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer. Weissbach L., Stuerzebecher S., Mumperow E., Klotz T., Schnell D. 2016
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Widmark A., Gunnlaugsson A., Beckman L., Thellenberg-Karlsson C., Hoyer M., Lagerlund M., Kindblom J., Ginman C., Johansson B., Björnlinger K., Seke M., Agrup M., Fransson P., Tavelin B., Norman D., Zackrisson B., Anderson H., Kjellén E., Franzén L., Nilsson P. 2019
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. Wilt TJ., Jones KM., Barry MJ., Andriole GL., Culkin D., Wheeler T., Aronson WJ., Brawer MK. 2017
Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Xiang M., Nguyen PL. -- Not Found --
Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Yang DD., Muralidhar V., Nguyen PL., Buzurovic I., Martin NE., Mouw KW., Devlin PM., Trinh QD., Orio PF., King MT. 2017
Focal Laser Ablation Versus Radical Prostatectomy for Localized Prostate Cancer: Survival Outcomes From a Matched Cohort. Zheng X., Jin K., Qiu S., Han X., Liao X., Yang L., Wei Q. 2019
Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis. Ashamalla H., Guirguis A., McCool K., McVorran S., Mattes M., Metzger D., Oromendia C., Ballman KV., Mokhtar B., Tchelebi M., Katsoulakis E., Rafla S. -- Not Found --
Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Barocas DA., Chen V., Cooperberg M., Goodman M., Graff JJ., Greenfield S., Hamilton A., Hoffman K., Kaplan S., Koyama T., Morgans A., Paddock LE., Phillips S., Resnick MJ., Stroup A., Wu XC., Penson DF. 2013
Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. Bekelman JE., Mitra N., Handorf EA., Uzzo RG., Hahn SA., Polsky D., Armstrong K. 2015
Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience. Fosså SD., Nilssen Y., Kvåle R., Hernes E., Axcrona K., Møller B. 2014
Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. Fridriksson JÖ., Folkvaljon Y., Lundström KJ., Robinson D., Carlsson S., Stattin P. 2017
Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. Jackson MW., Amini A., Jones BL., Kavanagh B., Maroni P., Frank SJ., Mahmood U., Kudchadker RJ., Pugh TJ. -- Not Found --
The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients. Jiang R., Tomaszewski JJ., Ward KC., Uzzo RG., Canter DJ. 2015
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Lennernäs B., Majumder K., Damber JE., Albertsson P., Holmberg E., Brandberg Y., Isacsson U., Ljung G., Damm O., Nilsson S. 2015
Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study. Lu-Yao GL., Kim S., Moore DF., Shih W., Lin Y., DiPaola RS., Shen S., Zietman A., Yao SL. 2015
Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database. Ricco A., Hanlon A., Lanciano R. 2017
Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer. Vargas CE., Alam NB., Terk M., Niska JR., Cesaretti J., Swartz D., Vashi A., Kasraeian A., West CS., Blasser M., Moore C. 2019
Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. Dell'Oglio P., Boehm K., Trudeau V., Tian Z., Larcher A., Leyh-Bannurah SR., Moschini M., Capitanio U., Shariat SF., Briganti A., Montorsi F., Saad F., Karakiewicz PI. 2016
Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. Giacalone NJ., Wu J., Chen MH., Renshaw A., Loffredo M., Kantoff PW., D'Amico AV. 2016
External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. Cho E., Mostaghel EA., Russell KJ., Liao JJ., Konodi MA., Kurland BF., Marck BT., Matsumoto AM., Dalkin BL., Montgomery RB. 2015
Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Smith GD., Pickles T., Crook J., Martin AG., Vigneault E., Cury FL., Morris J., Catton C., Lukka H., Warner A., Yang Y., Rodrigues G. 2015
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. Vargas CE., Schmidt MQ., Niska JR., Hartsell WF., Keole SR., Doh L., Chang JH., Sinesi C., Rodriquez R., Pankuch M., Larson GL. -- Not Found --
Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter? Weller MA., Kupelian PA., Reddy CA., Stephans KL., Tendulkar RD. 2015

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: